phrykt

Ionis Pharmaceuticals Inc (IONS): who owns it and who trades it

As of Nov 16, 2026, IONS insiders reported 107 open-market sales worth $120M and 3 purchases worth $1.2M in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brett P Monia (CEO), with $30.3M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ionis Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IONS

510 funds and institutions reported IONS shares worth $14.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 14.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)14.9%
Capital World Investors13.1%
BlackRock, Inc.6.5%
Vanguard Portfolio Management LLC4.8%
Wellington Management Group LLP4.6%
Vanguard Capital Management LLC4.4%
Two Sigma Investments, LP3.8%
Royal Bank of Canada3.7%
State Street Corp2.6%
T. Rowe Price Investment Management, Inc.2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)24.63M14.90%$2B+0%
Capital World Investors21.67M13.11%$1.7B+2%
BlackRock, Inc.10.70M6.48%$849M+3%
Vanguard Portfolio Management LLC7.86M4.76%$623M+1%
Wellington Management Group LLP7.65M4.63%$607M+20%
Vanguard Capital Management LLC7.21M4.36%$572M+1%
Two Sigma Investments, LP6.25M3.78%$496M+7%
Royal Bank of Canada6.18M3.74%$490M+63%
State Street Corp4.33M2.62%$344M+8%
T. Rowe Price Investment Management, Inc.3.96M2.40%$314M-36%
Geode Capital Management, LLC3.58M2.17%$295M-10%
T. Rowe Price Associates3.18M1.93%$252M+5%
JPMorgan Chase & Co2.67M1.62%$216M–
Artisan Partners Limited Partnership2.64M1.60%$209M+28%
Tweedy, Browne Co LLC2.28M1.38%$181M+0%
Deep Track Capital, LP2.20M1.33%$174M+13%
Goldman Sachs Group Inc2.11M1.28%$167M+24%
Baker Bros. Advisors LP2.05M1.24%$162MNo change
Deerfield Management Company, L.P.1.98M1.20%$157MNo change
American Century Companies Inc1.95M1.18%$154M+17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IONS insiders reported $1.2M of open-market purchases and $120M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.2M
3 trades, 1 people
Sales, 12 months
$120M
107 trades, 18 people
Sales under a 10b5-1 plan
81%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 13, 2026

Purchases and sales by month

$47.4M$47.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Michael R HaydenDirectorPurchase5,000$29.64$148KForm 4
Oct 16, 2026Shannon L. DeversVice presidentSale1,357$43.54$59.1KForm 4
Oct 16, 2026Eric SwayzeVice presidentSale53$43.54$2.3KForm 4
Jul 31, 2026Michael R HaydenDirectorPurchase5,000$51.60$258KForm 4
Jul 30, 2026Michael R HaydenDirectorPurchase15,000$53.38$801KForm 4
Jul 7, 2026C Frank BennettVice presidentSale plan15,000$85.46$1.3MForm 4
Jul 7, 2026C Frank BennettVice presidentSale plan5,536$83.58$463KForm 4
Jul 7, 2026Allene M. DiazDirectorSale plan10,111$85.42$864KForm 4
Jul 7, 2026Holly B. KordasiewiczVice presidentSale plan362$84.30$30.5KForm 4
Jul 1, 2026Joseph Klein IIIDirectorSale plan99$79.45$7.9KForm 4
Jul 1, 2026Joseph Klein IIIDirectorSale plan11,419$79.04$903KForm 4
Jun 26, 2026Joseph BaroldiVice presidentSale plan5,635$80.16$452KForm 4
Jun 26, 2026Patrick R. O'NeilVice presidentSale plan3,069$80.00$246KForm 4
Jun 26, 2026Eugene SchneiderVice presidentSale plan26,000$81.05$2.1MForm 4
Jun 26, 2026Brett P MoniaCEOSale plan50,000$80.59$4MForm 4
Jun 25, 2026Brett P MoniaCEOSale plan21,072$78.49$1.7MForm 4
Jun 25, 2026Eric SwayzeVice presidentSale plan10,602$79.18$839KForm 4
Jun 24, 2026Brett P MoniaCEOSale plan14,565$78.41$1.1MForm 4
Jun 15, 2026Spencer R BerthelsenDirectorSale plan8,000$73.49$588KForm 4
Jun 12, 2026Holly B. KordasiewiczVice presidentSale plan19,842$74.05$1.5MForm 4
Jun 12, 2026Holly B. KordasiewiczVice presidentSale plan41,004$73.09$3MForm 4
Jun 1, 2026Spencer R BerthelsenDirectorSale plan8,000$75.67$605KForm 4
May 14, 2026Brett P MoniaCEOSale plan3,220$78.68$253KForm 4
May 13, 2026Brett P MoniaCEOSale plan1,316$78.01$103KForm 4
May 4, 2026Joseph LoscalzoDirectorSale plan17,781$75.58$1.3MForm 4
May 4, 2026Joseph LoscalzoDirectorSale plan59,508$74.90$4.5MForm 4
May 1, 2026Joseph Klein IIIDirectorSale plan8,680$73.35$637KForm 4
May 1, 2026Joseph Klein IIIDirectorSale plan1,431$74.45$107KForm 4
Apr 28, 2026Joseph BaroldiVice presidentSale plan1,626$71.79$117KForm 4
Apr 16, 2026Kyle JenneVice presidentSale4,902$75.17$368KForm 4
Apr 16, 2026Brian BirchlerVice presidentSale973$75.04$73KForm 4
Apr 16, 2026Joseph BaroldiVice presidentSale5,619$74.56$419KForm 4
Apr 15, 2026B Lynne ParshallDirectorSale plan534$76.97$41.1KForm 4
Apr 15, 2026B Lynne ParshallDirectorSale plan4,466$76.19$340KForm 4
Apr 2, 2026Shannon L. DeversVice presidentSale plan6,193$74.05$459KForm 4
Apr 1, 2026Joseph Klein IIIDirectorSale plan2,216$75.95$168KForm 4
Apr 1, 2026Joseph Klein IIIDirectorSale plan20,105$75.50$1.5MForm 4
Mar 19, 2026Eugene SchneiderVice presidentSale plan5,812$70.97$412KForm 4
Mar 17, 2026Elizabeth L HougenCFOSale plan10,172$73.21$745KForm 4
Mar 16, 2026Elizabeth L HougenCFOSale plan205,608$72.38$14.9MForm 4
Mar 16, 2026Elizabeth L HougenCFOSale plan9,440$72.77$687KForm 4
Mar 10, 2026Brett P MoniaCEOSale plan16,512$75.47$1.2MForm 4
Mar 10, 2026Brett P MoniaCEOSale plan17,591$76.34$1.3MForm 4
Mar 10, 2026Kyle JenneVice presidentSale plan16,086$76.30$1.2MForm 4
Mar 10, 2026Kyle JenneVice presidentSale plan21,191$75.50$1.6MForm 4
Mar 9, 2026Patrick R. O'NeilVice presidentSale plan10,148$75.25$764KForm 4
Mar 9, 2026Brett P MoniaCEOSale plan1,684$75.58$127KForm 4
Mar 9, 2026Brett P MoniaCEOSale plan117,604$75.26$8.9MForm 4
Mar 9, 2026Brett P MoniaCEOSale plan7,382$74.11$547KForm 4
Mar 4, 2026Joseph LoscalzoDirectorSale plan200$80.00$16KForm 4
Mar 4, 2026Joseph BaroldiVice presidentSale plan238$80.00$19KForm 4
Mar 4, 2026Joseph BaroldiVice presidentSale plan201$80.00$16.1KForm 4
Mar 3, 2026Joseph LoscalzoDirectorSale plan832$80.33$66.8KForm 4
Mar 3, 2026Joseph Klein IIIDirectorSale plan13,526$79.17$1.1MForm 4
Mar 3, 2026Joseph Klein IIIDirectorSale plan6,794$80.00$544KForm 4
Mar 3, 2026Joseph Klein IIIDirectorSale plan1,012$80.82$81.8KForm 4
Mar 3, 2026Allene M. DiazDirectorSale plan14,608$79.88$1.2MForm 4
Mar 3, 2026Allene M. DiazDirectorSale plan1,005$80.80$81.2KForm 4
Mar 3, 2026Allene M. DiazDirectorSale plan39,265$79.11$3.1MForm 4
Mar 3, 2026Shannon L. DeversVice presidentSale plan14,321$79.12$1.1MForm 4
Mar 3, 2026Shannon L. DeversVice presidentSale plan5,030$80.00$402KForm 4
Mar 3, 2026Shannon L. DeversVice presidentSale plan755$80.84$61KForm 4
Mar 3, 2026C Frank BennettVice presidentSale plan71,600$79.10$5.7MForm 4
Mar 3, 2026C Frank BennettVice presidentSale plan12,687$79.88$1MForm 4
Mar 3, 2026C Frank BennettVice presidentSale plan802$80.76$64.8KForm 4
Mar 3, 2026Joseph BaroldiVice presidentSale plan2,088$80.41$168KForm 4
Mar 3, 2026Joseph BaroldiVice presidentSale plan36$81.01$2.9KForm 4
Mar 3, 2026Joseph BaroldiVice presidentSale plan4,096$79.36$325KForm 4
Feb 13, 2026Eric SwayzeVice presidentSale plan6,207$82.07$509KForm 4
Feb 13, 2026Eric SwayzeVice presidentSale plan9,435$81.56$770KForm 4
Feb 11, 2026B Lynne ParshallDirectorSale plan5,000$82.72$414KForm 4
Feb 6, 2026Brett P MoniaCEOSale plan29,430$85.79$2.5MForm 4
Feb 2, 2026C Frank BennettVice presidentSale plan16,463$83.03$1.4MForm 4
Feb 2, 2026C Frank BennettVice presidentSale plan48,626$83.03$4MForm 4
Feb 2, 2026C Frank BennettVice presidentSale plan20,000$82.60$1.7MForm 4
Jan 30, 2026Eric SwayzeVice presidentSale6,179$82.93$512KForm 4
Jan 30, 2026Eugene SchneiderVice presidentSale6,179$83.45$516KForm 4
Jan 30, 2026Patrick R. O'NeilVice presidentSale6,179$83.53$516KForm 4
Jan 30, 2026Brett P MoniaCEOSale62,970$82.72$5.2MForm 4
Jan 30, 2026Elizabeth L HougenCFOSale6,988$83.24$582KForm 4
Jan 30, 2026Brian BirchlerVice presidentSale6,179$83.03$513KForm 4
Jan 30, 2026C Frank BennettVice presidentSale5,885$82.95$488KForm 4
Jan 30, 2026Joseph BaroldiVice presidentSale5,296$82.96$439KForm 4
Jan 22, 2026Shannon L. DeversVice presidentSale plan3,977$81.34$323KForm 4
Jan 16, 2026Eric SwayzeVice presidentSale9,884$75.34$745KForm 4
Jan 16, 2026Eric SwayzeVice presidentSale49$75.97$3.7KForm 4
Jan 16, 2026Eugene SchneiderVice presidentSale9,302$75.59$703KForm 4
Jan 16, 2026Patrick R. O'NeilVice presidentSale9,191$75.84$697KForm 4
Jan 16, 2026Brett P MoniaCEOSale44,034$74.82$3.3MForm 4
Jan 16, 2026Holly B. KordasiewiczVice presidentSale4,141$75.66$313KForm 4
Jan 16, 2026Kyle JenneVice presidentSale1,823$75.96$138KForm 4
Jan 16, 2026Elizabeth L HougenCFOSale12,922$75.22$972KForm 4
Jan 16, 2026Shannon L. DeversVice presidentSale8,353$75.95$634KForm 4
Jan 16, 2026Brian BirchlerVice presidentSale8,480$75.11$637KForm 4
Jan 16, 2026C Frank BennettVice presidentSale8,977$75.15$675KForm 4
Jan 16, 2026Joseph BaroldiVice presidentSale6,907$75.75$523KForm 4
Jan 16, 2026Joseph BaroldiVice presidentSale1,149$75.78$87.1KForm 4
Jan 7, 2026Shannon L. DeversVice presidentSale plan25,545$85.36$2.2MForm 4
Jan 7, 2026Shannon L. DeversVice presidentSale plan2,101$85.36$179KForm 4
Jan 7, 2026Shannon L. DeversVice presidentSale plan9,264$84.62$784KForm 4

Latest 100 of 110 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brett P MoniaChief Executive Officer, Director–$30.3MJun 26, 2026
Elizabeth L HougenEVP, Finance & CFO–$17.9MMar 17, 2026
C Frank BennettEVP, Chief Scientific Officer–$16.7MJul 7, 2026
Shannon L. DeversEVP, Chief Human Resources Ofc–$8.2MOct 16, 2026
Joseph LoscalzoDirector–$5.9MMay 4, 2026
Joseph Klein IIIDirector–$5.4MJul 1, 2026
Eric SwayzeEVP Research–$5.2MOct 16, 2026
Allene M. DiazDirector–$5.2MJul 7, 2026
Holly B. KordasiewiczEVP, Chief Development Officer–$4.8MJul 7, 2026
Eugene SchneiderEVP, Chf Clinical Develop Ofcr–$3.7MJun 26, 2026
Kyle JenneEVP, Chf GL Pdt Str Ofcr–$3.3MApr 16, 2026
Joan E HermanDirector–$3.2MNov 19, 2025
Joseph BaroldiEVP, Chief Business Officer–$2.6MJun 26, 2026
Joseph H WenderDirector–$2.3MDec 1, 2025
Patrick R. O'NeilEVP CLO & General Counsel–$2.2MJun 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IONS short interest

High short interest. 12.7% of IONS shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 21.17M IONS shares were sold short, 12.7% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 2.52M shares, buying them all back would take about 8.4 trading days (days to cover).

Shares short, % of all shares

12.7%May 15Oct 3014.1%

Days to cover

8.4May 15Oct 3011.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202621.17M12.74%+2%2.52M8.4
Oct 15, 202620.65M12.43%-8%2.70M7.7
Sep 30, 202622.51M13.54%+8%4.88M4.6
Sep 15, 202620.89M12.57%-0%4.02M5.2
Aug 31, 202620.92M12.59%+0%2.28M9.2
Aug 14, 202620.91M12.58%-3%2.17M9.6
Jul 31, 202621.47M12.92%+7%3.38M6.3
Jul 15, 202620.04M12.13%+15%5.45M3.7
Jun 30, 202617.43M10.54%-2%2.38M7.3
Jun 15, 202617.76M10.74%+5%1.67M10.6
May 29, 202616.99M10.28%+6%1.70M10.0
May 15, 202616.09M9.73%-1%1.61M10.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ionis Pharmaceuticals company events

Ionis Pharmaceuticals filed 20 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 23, 2026AnnouncementIonis’ partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgAN receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1%… Filing
  3. Oct 21, 2026AnnouncementIonis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of CHB virus infection in combination with NrtI therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV DNA, and with HBsAg… Filing
  4. Sep 23, 2026AnnouncementIonis and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with IgAN. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful… Filing
  5. Sep 4, 2026AnnouncementIonis announced that its partner, Novartis, reported that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction… Filing
  6. Sep 4, 2026AnnouncementIonis announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) for the treatment of AxD in pediatric and adult patients. Filing
  7. Jul 29, 2026ResultsReleased financial results. Filing
  8. Jul 10, 2026AnnouncementShared information with investors. Filing
  9. Jul 9, 2026AnnouncementIonis announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to Week 140 compared with placebo. Filing
  10. Jun 24, 2026AnnouncementIonis announced that the U.S. FDA has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG. TRYNGOLZA is available in a 50 mg or 80 mg dose and is self-administered once monthly via an autoinjector. sHTG is… Filing
  11. Jun 12, 2026AnnouncementIonis Pharmaceuticals, Inc. shared positive new data from the open-label extension study of CORE and CORE2 evaluating olezarsen in people with severe hypertriglyceridemia during an oral presentation at the National Lipid Association Scientific Sessions in Chicago. Filing
  12. Jun 8, 2026LeadershipThe Board of Directors of Ionis Pharmaceuticals, Inc. appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders. Filing
  13. May 28, 2026AnnouncementIonis announced that its partner, GSK, reported positive pivotal data for bepirovirsen, an investigational ASO for the treatment of CHB. Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European… Filing
  14. Apr 29, 2026ResultsReleased financial results. Filing
  15. Apr 21, 2026AnnouncementWe announced additional positive results from the pivotal study of zilganersen in children and adults living with AxD, a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Filing
  16. Mar 9, 2026LeadershipB. Lynne Parshall, a member of the Board of Directors of Ionis Pharmaceuticals, Inc., and member of the Compliance Committee and Finance Committee of the Board, notified the Company that she will be retiring from the Board at the end of her current term and not seeking re-election at the Company’s… Filing
  17. Feb 25, 2026ResultsReleased financial results. Filing
  18. Jan 12, 2026ResultsReleased financial results. Filing
  19. Jan 7, 2026AnnouncementWe announced that our partner, GSK, reported positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational ASO for the treatment of CHB. The studies included over 1,800 patients from 29 countries. Filing
  20. Nov 17, 2025AgreementIonis Pharmaceuticals, Inc. completed its previously announced private offering of $770.0 million of 0.00% Convertible Senior Notes due 2030, including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ionis Pharmaceuticals financials

Famous investors that hold IONS

7 of the 50 well-known investors we track reported holding IONS in their latest 13F filing. The largest position is Ken Griffin's, worth $180M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20264.03M$180M0.1%+1604%
Steve Cohen · Point72 Asset ManagementQ3 20261.23M$54.8M0.1%New
Cathie Wood · ARK Investment ManagementQ3 2026923,162$41.2M0.2%+207%
Israel Englander · Millennium ManagementQ3 2026750,785$33.5M0.0%+160%
Jim Simons · Renaissance TechnologiesQ3 2026354,214$15.8M0.0%-37%
Ken Fisher · Fisher Asset ManagementQ3 2026182,997$8.2M0.0%+33%
Paul Tudor Jones · Tudor Investment CorpQ3 202623,882$1.1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Ionis Pharmaceuticals Inc (IONS) stock

Who owns the most IONS stock?

The largest reported owner of Ionis Pharmaceuticals Inc (IONS) is FMR LLC (Fidelity), with 14.9% of the company. In total, 510 funds and institutions reported holding IONS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IONS insiders buying or selling?

In the last 12 months, IONS insiders reported 3 open-market purchases worth $1.2M and 107 sales worth $120M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in IONS?

As of Oct 30, 2026, 21.17M IONS shares were sold short, 12.7% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 2.52M shares, buying them all back would take about 8.4 trading days (days to cover). See the history.

Which famous investors hold IONS?

7 of the 50 well-known investors we track reported IONS in their latest 13F filing, including Ken Griffin, Steve Cohen, Cathie Wood. The largest position is worth $180M. See all holders.

Executive pay

Ionis Pharmaceuticals's chief executive was paid a total of $13.4M for the year ended Dec 31, 2025, down 13% from $15.4M the year before. In the last 12 months, Ionis Pharmaceuticals's executives and directors bought $1.2M of stock on the open market and sold $120M.

Chief executive, total pay$13.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$42.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.